Muhammad Muaz Mushtaq

Dr. Muhammad Muaz Mushtaq


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2024 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
MMMuhammad Muaz Mushtaq
Muhammad Muaz Mushtaq
MMMaham Mushtaq
Maham Mushtaq
HAHusnain Ali
Husnain Ali
MSMuhammad Asad Sarwar
Muhammad Asad Sarwar
DBDr. Syed Faqeer Hussain Faqeer Hussain Bokhari
Dr. Syed Faqeer Hussain Faqeer Hussain Bokhari

7 July 2024 in Cureus
Verified
Journal Article
Open access
PDF file
SRShuja Ur Rehman
Shuja Ur Rehman
NKNikhil Deep Kolanu
Nikhil Deep Kolanu
MMMuhammad Muaz Mushtaq
Muhammad Muaz Mushtaq
HAHusnain Ali
Husnain Ali
ZAZeeshan Ahmed
Zeeshan Ahmed
DBDanyal Bakht
Danyal Bakht
Diabetic kidney disease (DKD) is a prevalent microvascular complication of diabetes, posing a significant health burden. Semaglutide, a glucagon-like peptide-1 receptor agonist, has shown promise in mitigating renal outcomes in DKD. This systematic review aimed to evaluate the renal effects of semaglutide in individuals with DKD. A comprehensive literature search identified six eligible studies, including two case reports and four cohorts, from diverse geographic locations. The primary outcomes assessed were changes in estimated glomerular filtration rate (eGFR) and albuminuria. Secondary outcomes included acute kidney injury (AKI) incidence and other renal biomarkers. The impact of semaglutide on eGFR was variable, with some studies reporting decreases and others showing improvements or no significant changes. Albuminuria, however, was more consistently reduced, particularly in patients with macroalbuminuria. Notably, the case reports described semaglutide-associated AKI, including acute interstitial nephritis, highlighting the need for careful monitoring during therapy. Beyond renal outcomes, semaglutide consistently improved glycemic control and promoted weight loss, with generally manageable gastrointestinal side effects. The findings suggest that semaglutide may effectively reduce albuminuria in DKD, potentially slowing disease progression. However, the risk of AKI and the variable impact on eGFR underscore the need for a personalized approach and vigilant monitoring, particularly in patients with advanced CKD. Future large-scale, long-term randomized controlled trials are warranted to definitively assess the renal benefits and risks of semaglutide in DKD.

13 July 2024 in Cureus
Verified
Journal Article
Open access
MBMohammad Burhanuddin
Mohammad Burhanuddin
VJVaishnavi Jamched
Vaishnavi Jamched
MHMuhammad Haris
Muhammad Haris
HAHusnain Ali
Husnain Ali
MMMuhammad Muaz Mushtaq
Muhammad Muaz Mushtaq
SBSyed Faqeer Hussain Bokhari
Syed Faqeer Hussain Bokhari
Atrial fibrillation (AF) is a common cardiac arrhythmia with a significant impact on patient outcomes and healthcare systems. Given the rising incidence of AF with age and its association with conditions, such as diabetes, there is growing interest in exploring pharmacological interventions that might mitigate AF risk. Metformin, a widely prescribed antihyperglycemic agent for type 2 diabetes mellitus (T2DM), has demonstrated various cardiovascular benefits, including anti-inflammatory and antioxidative properties, leading to speculations about its potential role in AF prevention. This systematic review synthesizes findings from five studies examining the association between metformin use and AF risk in patients with T2DM. The review included a dynamic cohort study, three retrospective cohort studies, and a case report, all sourced from databases, such as PubMed, Embase, and the Cochrane Library. The results are mixed; while some studies suggest that metformin use is linked to a reduced incidence of AF, others report no significant association, particularly in postoperative settings. The largest cohort study highlighted a dose-response relationship, suggesting prolonged metformin use correlates with lower AF risk. Conversely, a case report raised concerns about metformin-induced lactic acidosis potentially triggering AF episodes. The review underscores the heterogeneity in study designs and outcomes, pointing to the need for more robust research to establish causality and clarify underlying mechanisms. Future studies should prioritize prospective designs and explore the pleiotropic effects of metformin on atrial remodeling and electrophysiology to better understand its potential role in AF prevention.

21 August 2026 in Cureus
Verified
Journal Article
Open access
PDF file
AKAbhishek Hanumanpratap Singh Kshatri
Abhishek Hanumanpratap Singh Kshatri
SASamia Arif
Samia Arif
SYSadia Yousaf
Sadia Yousaf
MHMuhammad Habib
Muhammad Habib
MSMinahil Saif
Minahil Saif
MMMuhammad Muaz Mushtaq
Muhammad Muaz Mushtaq
Iron deficiency is a distinct comorbidity in patients with heart failure (HF), independent of anemia, and is associated with reduced functional capacity and increased hospitalization and mortality. Randomized trials of intravenous (IV) iron repletion have yielded directionally consistent but incompletely aligned results, prompting numerous systematic reviews and meta-analyses that largely draw on the same underlying trials. We performed an umbrella review to consolidate this evidence base and clarify the strength and consistency of treatment effects across outcomes. Across the pooled reviews, IV iron, predominantly ferric carboxymaltose (FCM), reduced the composite risk of HF hospitalization and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), an effect attributable chiefly to fewer hospitalizations rather than a survival benefit, which remained non-significant throughout. Functional capacity, symptom class, and quality of life improved consistently. Safety appeared favorable among the outcomes formally assessed, though fewer than half of the included reviews performed a dedicated statistical safety analysis, and known formulation-specific risks such as hypophosphatemia were not evaluated in this literature. The treatment effect appeared attenuated in the one review restricted to acute heart failure, and possible differences in benefit by sex and by baseline iron-transport capacity emerged as hypothesis-generating candidate explanations for residual heterogeneity, warranting prospective confirmation rather than immediate clinical application. Evidence was drawn predominantly from FCM trials, with more limited supporting data for ferric derisomaltose and minimal data for other formulations; findings should not be extrapolated beyond HFrEF, as HF with preserved ejection fraction populations were not separately represented in this literature. Because the available reviews draw heavily on a shared and aging set of trials (corrected covered area of 31.9%, indicating very high primary-study overlap), this synthesis should be regarded as clarifying rather than expanding the evidence base. Taken together, IV iron repletion, particularly with FCM, in iron-deficient HFrEF reduces hospitalizations and improves quality of life, but a mortality benefit has not been established, underscoring the need for adequately powered trials designed specifically to resolve this question.